Enzolytics Inc (ENZC)

[falon]

What is ENZC?

A little ole Biotech Committed to the Development of Proprietary Antiviral Peptides and Monoclonal Antibody for Treating Debilitating Infectious Diseases

What is ENZC Mission?

Our mission is clear – to create therapeutics that are effective and affordable for treating infectious diseases that plague the world. This goal includes the development of therapeutics and monoclonal antibodies targeting infectious diseases, including the CoronaVirus.
Our ultimate objective is to provide such therapeutics to improve health around the world.


What is their plan of action?

Enzolytics, Inc. is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Enzolytics is committed to developing monoclonal antibody therapy and treating infectious diseases.

What assets does ENZC possess?

Intellectual property:

2 Patents with 14+ patents pending.

Proprietary Cell Line Producing Clone 3 anti-HIV monoclonal antibody

Proprietary Methodology for Producing Fully Human Monoclonal Antibodies

Human Capital:

Charles S. Cotropia – CEO and Chairman of the Board

Joseph P. Cotropia, MD – Chief Medical Officer and Director

Harry H. Zhabilov – CSO and Director

Gaurav Chandra, MD – Chief Operating Officer and Director

Ronald Moss, MD – Scientific Advisor

RABID Shareholders:)

Who are our Partnering Labs For Implementing Our Technologies?

Genscript Labs
The production of recombinant Monoclonal Antibodies from parent antibodies, necessary for patient treatment.

University of Strasbourg, France
Dr. Christiane Moog, MD, Research Director at INSERM U1109, HDR PBMC, In vitro neutralization testing of anti-HIV Monoclonal Antibodies.

California National Primate Research Center
Koen Van Rompay, D.V.M., Ph.D., Univ. of California Davis, California, Koen Van Rompay. Macaque trials of anti-HIV Monoclonal Antibodies.

Creative Biolabs
Custom recombinant Monoclonal Antibody production and large-scale antibody manufacturing.

Samsung Biologics
Enzolytics Inc. to leverage Samsung Biologics' development and manufacturing expertise to advance both Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibody Therapies to IND.

Samsung Biologics to offer a seamless, end-to-end CDMO service with support from its San Francisco R&D Center.

These Partnering labs are there to assist in moving our technology forward.

Just think about what Charles said about the licensees already lining up to get a piece of the ever growing pie.

Every time ENZC reaches a significant milestone they become more and more valuable.

We are encouraged by the positive feedback received from pharmaceutical companies who have acknowledged an interest in partnering upon achievement of defined milestones.

That statement above will come to be after certain milestones are met and then BIG Pharma comes into play. It is my belief that ENZC may license/sell certain technologies (first with HIV and Covid 19 therapies) however if ENZC wants to ensure all their possible technologies make it to the marketplace they have to continue to develop the technologies for other diseases.

If ENZC was to sell the company outright then whoever buys it can do what they want with the technology.

Dr. Chandra said is best during a previous video:

This is very exciting

We have had discussions with large pharmaceutical companies.

There are tremendous interest in both the antibodies.

We have been offered interest in collaboration, partnership/acquisition of assets with a milestone based requirement.

We anticipate there will be a partnership with a larger entity before the twelve month period when the IND will be applied on both of the antibodies.

Final Thoughts:

We all are here to make money however as most know there are no guarantees.

This is a HIGH Risk HIGH REWARD investment. The risk goes down everyday as we move closer to certain milestones.

There are some predictive patterns to how biotech stocks start impressive runs and sometime Big Money loses patience and decides to make a move.

The current company only got started a year ago and look at all what it has accomplished. There has been bumps in the road and ENZC made adjustments to continue on to their objectives. One of the biggest setbacks was having to do the clinical trials again in Europe. Charles rolled up his sleeves and figured out what to do.

There will more bumps and more adjustments and I'm confident Charles will figure it out.

The Pot of GOLD is just months away however there will be nuggets leading us there along the way.

“Our world is built on biology and once we begin to understand it, it then becomes a technology”? Ryan Bethencourt